|Ms. Bonnie H. Anderson||Co-Founder, Chairman & CEO||1.07M||N/A||1958|
|Mr. Keith S. Kennedy CFA, CPA||CFO, COO & Sec.||869.1k||N/A||1970|
|Mr. Mark Ho||Principal Accounting Officer||N/A||N/A||1973|
|Dr. Giulia C. Kennedy Ph.D.||Chief Scientific & Medical Officer||N/A||N/A||1959|
|Mr. Ashish Kheterpal||Chief Information Officer||N/A||N/A||N/A|
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 8.